Phase 1 open-label, multicenter, dose-escalation clinical study of the safety and tolerability of SNS-032, a novel cyclin-dependent kinase inhibitor, administered to patients with select advanced solid tumors
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2012
At a glance
- Drugs SNS 032 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Sunesis Pharmaceuticals
- 06 Jun 2012 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2007 Status changed from recruiting to in progress.